Dexcom to Present at the Oppenheimer & Company 23rd Annual Healthcare Conference
Dexcom to Present at the Oppenheimer & Company 23rdAnnual Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)-- Dexcom, Inc. (NAS: DXCM) today announced that Steve Pacelli, Executive Vice President of Strategy and Corporate Development, will present an update on the company at the Oppenheimer & Company 23rd Annual Healthcare Conference in New York on Wednesday, December 12 at 9:25 a.m. (EST). The presentation, which will occur live at the Waldorf-Astoria, will be concurrently webcast. The link to the webcast will be available on the Dexcom, Inc. website at www.dexcom.com under the investor relations, events and webcast section, and will be archived for future reference.
About Dexcom, Inc.
Dexcom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients and by healthcare providers in the hospital.
Cautionary Statement Regarding Forward Looking Statements
Dexcom is a medical device company with a limited operating history. Successful commercialization of the company's products is subject to numerous risks and uncertainties, including a lack of acceptance in the marketplace by physicians and patients, the inability to manufacture products in commercial quantities at an acceptable cost, possible delays in the company's development programs, the inability of patients to receive reimbursement from third-party payors and inadequate financial and other resources. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's quarterly report on Form 10-Q for the period ending September 30, 2012, as filed with the Securities and Exchange Commission on November 1, 2012.
Steven R. Pacelli
Executive Vice President, Strategy and Corporate Development
KEYWORDS: United States North America California New York
The article Dexcom to Present at the Oppenheimer & Company 23rd Annual Healthcare Conference originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.